News

The molecular properties of nipocalimab determine its ability for preventing FNAIT without compromising other immune functions.

Preclinical data published by Johnson & Johnson support the therapeutic promise of nipocalimab in IgG-driven diseases such as FNAIT.

Posttransfusion purpura is a rare but serious immune response that can lead to severe platelet loss and bleeding.

A recent study summarizes various types of thrombocytopenia, including FNAIT, detailing their causes, clinical presentations and treatments.

The first patient has been dosed in a Phase 2 study that will test the efficacy of a monoclonal antibody in pregnant women at risk of FNAIT.

Neonatal intraventricular hemorrhage, a potential FNAIT complication, is most frequent six hours after birth in preterm infants.

A recent study showed that pregnant mothers with hypertension or preeclampsia may be at a higher risk of developing FNAIT.

Evaluating plasma thrombopoietin (TPO) levels among neonates with low platelet counts has been shown to speed up diagnosis and treatment.

A recent review article describes the current guidelines for various hematological pregnancy complications including FNAIT.

In a recent case study, maternal antibodies likely transferred through breastfeeding caused delayed thrombocytopenia in a newborn.